Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

Key Takeaways LLY's tirzepatide drugs now drive 50% of revenues, with global demand fueling momentum. MRK relies heavily on Keytruda but faces headwinds in China and looming patent expirations. LLY forecasts up to 32% sales growth in 2025, while MRK's EPS and revenue estimates continue to decline.Both Eli Lilly (LLY) and Merck (MRK) are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas. While Lilly ...